Samsung Biologics Secures $262M Long-Term Manufacturing Contract Through 2033
- Samsung Biologics signed a $262 million manufacturing agreement with a European pharma company, with commitments extending through 2033 at its Songdo, South Korea facility.
- The deal brings Samsung Biologics' cumulative contract value to over $21.9 billion, reflecting sustained demand and rapid capacity booking across its global network.
Operational Impact
Samsung Biologics' Songdo facility now carries committed manufacturing through 2033, reducing available capacity for new client onboarding and reinforcing the company's position as a capacity-constrained CDMO vendor in the biologics market.
Source: Contract Pharma Breaking News RSS